You are here: Home » International » News » Others
Vladimir Putin says he allowed foe Alexie Navalny to get treatment abroad
Goldman to pay $3 bn, claw back executive pay over role in 1MDB scandal
Business Standard

USFDA approves first coronavirus treatment drug - antiviral remdesivir

US regulators approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given through an IV for patients needing hospitalization

Topics
Coronavirus Vaccine | USFDA

AP  |  Washington 



Vaccine, Covid

US regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given through an IV for patients needing hospitalization.

The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days from 15 days to 10 on average in a large study led by the US National Institutes of Health.

It had been authorized for use on an emergency basis since spring, and now becomes the first drug to win full Food and Drug Administration approval for treating COVID-19. President Donald Trump received it when he was sickened earlier this month.

Veklury is approved for people at least 12 years old and weighing at least 40 kilograms who need hospitalization for their coronavirus infection. For patients younger than 12, the FDA will still allow the drug's use in certain cases under its previous emergency authorization.

The drug works by inhibiting a substance the virus uses to make copies of itself. Certain tests are required before starting patients on it. And the label warns against using it with the malaria drug hydroxychloroquine, because that can curb its effectiveness.

"We now have enough knowledge and a growing set of tools to help fight COVID-19," Gilead's chief medical officer, Dr Merdad Parsey, said in a statement.

The drug is either approved or has temporary authorization in about 50 countries, he noted.

Its price has been controversial, given that no studies have found it improves survival. Last week, a large study led by the World Health Organization found the drug did not help hospitalized COVID-19 patients, but that study did not include a placebo group and was less rigorous than previous ones that found a benefit.

Gilead charges USD 2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries, and USD 3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.

Only one treatment steroids such as dexamethasone has been shown so far to cut the risk of dying of COVID-19.

The FDA also has given emergency authorization to using the blood of survivors and two companies are currently seeking similar authorization for experimental antibody drugs.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Fri, October 23 2020. 07:44 IST

RECOMMENDED FOR YOU

.